MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41598-026-36712-x

Медицинская библиотека · Scientific reports · 2026

Can evolutionary therapy be applied in non-small cell lung cancer?

Jansén-Storbacka Laura R, Honasoge Kailas S, Molnárová Eva, Soboleva Arina, Agema Bram C, Paats Marthe S, Moes Dirk Jan A R, Veerman G D Marijn, Barbaro Alethea B T, Dobbe Roel, Grossmann Irene, Azimi Sepinoud, Mathijssen Ron H J, Dingemans Anne-Marie C, Staňková Kateřina

СтатьяПеревод пока не подготовлен

Аннотация

Evolutionary therapy (ET) applies principles of evolutionary biology to steer tumour dynamics and forestall or delay treatment resistance, typically guided by data-driven mathematical models. Our aim is to assess whether ET protocols, and specifically Zhang et al.'s protocol proposed for metastatic castrate-resistant prostate cancer, can be theoretically effective for fast-growing metastatic cancers such as stage IV non-small-cell lung cancer (NSCLC). Using longitudinal tumour-burden data from NSCLC patients treated with erlotinib, we systematically evaluate 26 two-population differential-equation models based on classical tumour-growth dynamics, with varying assumptions about density- and frequency-dependent interactions, pharmacokinetics, and treatment-induced death. Previous work by Yin et al. on the same dataset employed an exponential model that omitted density- and frequency-dependent interactions; although it provided a good fit to tumour-burden data, its structure would theoretically lead to poorer outcomes under ET protocols. In contrast, our analysis identifies the minimal model structure required to reproduce the resistance-driven regrowth observed in NSCLC, with the Gompertzian model featuring log-kill dynamics and both density- and frequency-dependent interactions providing the best fit. In this model, Zhang et al.'s protocol prolonged median time-to-progression to 42.3 months compared with 24.8 months under maximum tolerated dose. These results indicate that ET is theoretically a viable treatment strategy for NSCLC. This study offers a practical framework for assessing ET feasibility using clinical data and supports future clinical translation of ET in NSCLC.

Для цитирования: Jansén-Storbacka Laura R, Honasoge Kailas S, Molnárová Eva, Soboleva Arina, Agema Bram C, Paats Marthe S, Moes Dirk Jan A R, Veerman G D Marijn, Barbaro Alethea B T, Dobbe Roel, Grossmann Irene, Azimi Sepinoud, Mathijssen Ron H J, Dingemans Anne-Marie C, Staňková Kateřina. Can evolutionary therapy be applied in non-small cell lung cancer?. Scientific reports. 2026. DOI: 10.1038/s41598-026-36712-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.